Aptose Biosciences Inc. 8-K

What Happened

• Aptose Biosciences Inc. announced via an 8‑K (filed July 1, 2026) that it issued a press release on June 30, 2026. The press release is attached to the filing as Exhibit 99.1 and was disclosed under Item 7.01 (Regulation FD Disclosure).
• The filing notes, per Form 8‑K instruction, that the press release is furnished (not “filed”) for purposes of Section 18 of the Securities Exchange Act and is not incorporated by reference into other filings unless explicitly stated.

Key Details

• Press release date: June 30, 2026. 8‑K filed: July 1, 2026.
• Exhibit: 99.1 contains the full press release; the Inline XBRL cover page (Document 104) is also part of the submission.
• The company invoked General Instruction B.2 of Form 8‑K: the furnished press release is not deemed “filed” under the Exchange Act.

Why It Matters

• Regulation FD disclosures are intended to ensure material information is shared publicly and simultaneously — this 8‑K signals Aptose publicly released news that investors should review.
• Because the press release is furnished (not filed), it avoids Section 18 “filed” liability language but still conveys whatever operational, clinical, partnership or financial update Aptose chose to make; investors should read Exhibit 99.1 or the company’s website for the full details.
• If the press release contains material information, expect any follow-up (e.g., formal financial results, amendments, or additional filings) to appear in subsequent SEC filings.